Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platelet mass cytometry reveals dysregulation of prothrombotic pathways in essential thrombocythemia.
Dill V, Kirmes K, Han J, Klug M, Rosenbaum M, Viggiani G, von Scheidt M, List M, Herhaus P, Ruland J, Bassermann F, Laugwitz KL, Götze KS, Jost PJ, Jilg S, Bloxham CJ, Raake PWJ, Bernlochner I, Bongiovanni D. Dill V, et al. Platelets. 2024 Dec;35(1):2358244. doi: 10.1080/09537104.2024.2358244. Epub 2024 Jun 7. Platelets. 2024. PMID: 38845541 Free article.
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose.
Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V, Müller-Thomas C, Herold T, Prodinger PM, Schmidt B, Hempel D, Bassermann F, Peschel C, Götze KS, Höckendorf U, Haferlach T, Jost PJ. Jilg S, et al. Among authors: dill v. Exp Hematol Oncol. 2019 Apr 16;8:9. doi: 10.1186/s40164-019-0133-1. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 31016067 Free PMC article.
Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S. Dill V, et al. Eur J Haematol. 2020 Feb;104(2):125-137. doi: 10.1111/ejh.13354. Epub 2019 Dec 8. Eur J Haematol. 2020. PMID: 31758597 Clinical Trial.
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
Odinius TO, Buschhorn L, Wagner C, Hauch RT, Dill V, Dechant M, Buck MC, Shoumariyeh K, Moog P, Schwaab J, Reiter A, Brockow K, Götze K, Bassermann F, Höckendorf U, Branca C, Jost PJ, Jilg S. Odinius TO, et al. Among authors: dill v. J Cancer Res Clin Oncol. 2022 Feb;148(2):331-340. doi: 10.1007/s00432-021-03827-9. Epub 2021 Oct 15. J Cancer Res Clin Oncol. 2022. PMID: 34654952 Free PMC article.
Elevated RIPK3 correlates with disease burden in myelofibrosis.
Dill V, Wagner CV, Keller EC, Fernandez-Hernandez FJ, Shoumariyeh K, Odinius TO, Buschhorn L, Hauch RT, Suren C, Hecker JS, Herhaus P, Sandherr M, Schmidt B, Slotta-Huspenina J, Bassermann F, Höckendorf U, Jilg S, Branca C, Vosberg S, Jost PJ. Dill V, et al. Blood Adv. 2023 Apr 11;7(7):1219-1224. doi: 10.1182/bloodadvances.2021006838. Blood Adv. 2023. PMID: 36453650 Free PMC article. No abstract available.
40 results